Select Page

Press Releases

Sign up to get full access to all our latest Press Releases

Rapid Dose Announces Resumption of Trading on the CSE

May 4, 2023


BURLINGTON, Ontario – May 4, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that further to its press release dated May 2, 2023, trading in the Company’s common shares has resumed on the Canadian Securities Exchange.  About...

Rapid Dose Announces Revocation of Cease Trade Order

May 2, 2023


BURLINGTON, Ontario – May 2, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that on May 1, 2023, staff of the Ontario Securities Commission (the “OSC”) granted a full revocation of the failure-to-file cease trade order (“FFCTO”)...

Rapid Dose Announces Filing of Corrective Disclosure

April 14, 2023


BURLINGTON, Ontario – April 14, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that further to the review by the Ontario Securities Commission (“OSC”) of the Company’s continuous disclosure record, and a subsequent request from staff of the OSC in...

Rapid Dose Announces Board of Director Changes

April 14, 2023


BURLINGTON, Ontario – April 14, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is announcing changes to its board of directors. Jason Lewis has resigned as a director of the...

Rapid Dose Therapeutics Reports Fiscal Year 2022 Financial Results

February 1, 2023


BURLINGTON, Ontario – February 1, 2023 – On Friday, January 27, 2023, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), filed its financial results for the fiscal year ended February 28, 2022. Now that the Company has completed the filing of its audited...

Rapid Dose Therapeutics Reports Quarterly Financial Results for First Three Quarters of the 2023 Fiscal Year

February 1, 2023


BURLINGTON, Ontario – February 1, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), has filed its financial results for the first three quarters of the 2023 fiscal year. Now that the Company has completed the filing of its audited financial statements...

Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order

January 17, 2023


Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order BURLINGTON, Ontario – January 17, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release...

Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order

January 10, 2023


BURLINGTON, Ontario – January 10, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release dated December 20, 2022, the Company and its auditors are continuing to...

Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order

December 29, 2022


Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order BURLINGTON, Ontario – December 29, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release...

Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order

December 21, 2022


Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order BURLINGTON, Ontario – December 20, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release...

1 2 3 4 5 6 7 8 9 10 11 12 13 14